Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Studied

Randomized comparison of weekly semaglutide 2.4 mg with daily liraglutide 3.0 mg for weight loss, alongside diet and physical activity.

Who / model

338 adults with overweight or obesity and no diabetes, followed for 68 weeks; the trial also included placebo groups.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary comparison showed average weight loss of 15.8% with semaglutide versus 6.4% with liraglutide. For a confirmatory secondary outcome, 38.5% versus 6.0% lost at least 20%. Digestive adverse events occurred in 84.1% versus 82.7%. Treatment discontinuation for any reason was 13.5% versus 27.6%.

Limits

The active-drug comparison was unblinded. Semaglutide allowed dose reduction for intolerance; liraglutide required stopping, with an option to restart.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary